Patrik Brundin to give 2015 Edinburgh Parkinson’s Lecture
We are delighted to announce that Professor Patrik Brundin has accepted our invitation to deliver the 2015 Edinburgh Parkinson’s Lecture. The lecture will take place on the evening of 22…
Effects of high-risk Parkinson’s mutation may be reversible
Researchers from the University of Sheffield have found vital new evidence on how to target and reverse the effects caused by one of the most common genetic causes of Parkinson’s.…
How toxic proteins stress nerve cells
The research group led by Dr Mahalakshmi Subramaniam and Prof. Jochen Roeper at the Institute for Neurophysiology at the Goethe University, in collaboration with researchers from Frankfurt’s Experimental Neurology Group…
Phase III trial of Israpidine
Researchers at the University of California, San Diego School of Medicine have launched a Phase III clinical trial to evaluate the drug isradipine, a calcium channel blocker often used to…
Alpha Synuclein in the spotlight again
The protein alpha-synuclein is a well-known player in Parkinson’s disease and other related neurological conditions, such as dementia with Lewy bodies. Alpha-synuclein typically resides at presynaptic terminals — the communication…
Crowdfunding for Parkinson’s Research
A Scottish company, Parkure, part of the Edinburgh Science Triangle collaboration, is looking to raise a total of £100,000 from crowdfunding to help find a cure for Parkinson’s, which affects…
- « Previous Page
- 1
- ...
- 13
- 14
- 15
- 16
- 17
- ...
- 20
- ...
- 23
- Next Page »